Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Apomorphine”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 757 records · Page 42Linked to original sources

Effects of d,l-propranolol on apomorphine induced stereotyped behavior in rats.

The effects of d,l propranolol on stereotyped behavior induced by apomorphine administration was studied quantitatively. d,l Propranolol caused a 2.5 leftward displacement of the control dose-response curve constructed to apomorphine-induced stereotypy; the ED50 for apomorphine was reduced from 1.87 +/- 0.38 to 0.74 +/- 0.17. The potentiation was dependent on both d,l-propranolol and apomorphine doses. Results are discussed in the light of a possible interference of the central noradrenergic systems with the expression of dopaminergic-induced stereotyped behavior.

Animals↗

An investigation into the effects of apomorphine on the release of acetylcholine in the striatum of freely-moving rat using in vivo microdialysis.

1. Using in vivo microdialysis, we studied the effects of apomorphine on the release of acetylcholine (ACh) in the striatum of freely-moving rats. 2. Basal release of ACh was 3.01 +/- 0.51 pmol/15 min in 30 microliters (containing of 10 microM neostigmine) of the striatal perfusate. 3. Ringer containing tetrodotoxin (1 microM), hemicholinium-3 (5 mM), or Ca(2+)-free Ringer was perfused into the striatum. Each of these treatments produced a significant attenuation in release content of ACh. High K+ (30 mM) produced a significant increase in ACh release. 4. In normal rats, apomorphine (0.05 mg/kg, s.c.) increased striatal ACh release. A high dose (1.0 mg/kg) significantly attenuated release. 5. In 6-OHDA-pretreated rats, although the lower dose of apomorphine did not increase striatal ACh release, the high dose produced a more significant attenuation of release. 6. It is concluded that apomorphine enhanced or attenuated the striatal ACh release and that this effect was regulated by nigro-striatal dopaminergic system in the freely moving rats.

Acetylcholine↗

Effects of adenosine drugs on apomorphine-induced licking in rats.

1. In the present work, the effect of adenosine agonists and antagonists on apomorphine-induced licking has been studied. 2. Subcutaneous (s.c.) injection of apomorphine (0.125, 0.25 and 0.5 mg/kg) produced dose-dependent licking in rats. 3. Adenosine agonists 5'-N-ethylcarboxamide-adenosine (NECA) and N6-cyclohexyladenosine (CHA) decreased or increased the apomorphine response respectively. 4. Adenosine antagonists theophylline and 8-phenyltheophylline (8-PT) decreased the response induced by apomorphine. Potentiation of licking induced by CHA was decreased by 8-PT pretreatment. 5. It is concluded that adenosine receptors may be involved in the licking behaviour.

Adenosine↗

Dopaminergic transplants normalize amphetamine- and apomorphine-induced Fos expression in the 6-hydroxydopamine-lesioned striatum.

Dopamine receptor-mediated Fos protein expression in the striatum has been used to monitor dopamine receptor activation at the cellular level after dopaminergic denervation and reinnervation by fetal nigral transplants. The pattern of striatal Fos expression after systemic administration of either the dopamine receptor agonist, apomorphine, or the dopamine-releasing agent, amphetamine, was studied in rats which had received cell suspension grafts of fetal ventral mesencephalic neurons into the striatum after a complete 6-hydroxydopamine lesion of mesostriatal dopaminergic projection. Grafted animals, and normal and lesioned controls were killed 2 h after administration of either D-amphetamine (5 mg/kg, i.p.) or apomorphine (0.25 mg/kg, s.c.). Fos protein was detected immunohistochemically, and the density of Fos-immunoreactive cell nuclei was measured in 12 selected areas of caudate-putamen, nucleus accumbens and globus pallidus by computerized image analysis. Consistent with previous studies, amphetamine induced high Fos expression in the medial and dorsal parts of the intact caudate-putamen and significantly lower expression in the denervated caudate-putamen. A significant difference between lesioned and intact striata was present also in globus pallidus, but not in nucleus accumbens. In grafted rats, amphetamine-induced Fos activation was restored to normal or supranormal levels in the anterior and central caudate-putamen (i.e. close to the graft deposits), whereas in the tail of caudate-putamen Fos expression was significantly lower than normal. The side-to-side difference in globus pallidus seen in lesioned rats was no longer present in the grafted animals. Apomorphine led to high Fos activation throughout the dopamine-depleted caudate-putamen, whereas only very few immunopositive cells were observed in the intact caudate-putamen. Also in globus pallidus and nucleus accumbens, a significantly higher number of Fos-immunoreactive cells was detected on the denervated side. In the grafted rats, apomorphine-induced Fos activation was similar to normal in all striatal areas sampled, as well as in the globus pallidus. The graft-induced effect extended over a considerably larger area than that covered by the graft-derived tyrosine hydroxylase-immunoreactive innervation. These findings indicate that fetal ventral mesencephalic transplants normalize dopamine receptor-mediated function in the 6-hydroxydopamine-lesioned caudate-putamen and nucleus accumbens, as well as in a primary target of the striatal output neurons, the globus pallidus. The results support the idea that dopamine released from the grafted neurons, both under baseline conditions and after amphetamine administration, exerts functional effects over a larger volume of the striatum than that reached by the graft-derived fibers.

Animals↗

An investigation into the role of the pedunculopontine tegmental nucleus in the mediation of locomotion and orofacial stereotypy induced by d-amphetamine and apomorphine in the rat.

As the pedunculopontine tegmental nucleus has an important anatomical position as an output station for the striatum, its role in the mediation of behaviour stimulated by d-amphetamine and apomorphine was investigated. Bilateral ibotenate lesions were made in either the pedunculopontine tegmental nucleus or, as a control, in the adjacent deep mesencephalic nucleus; sham lesions were made using phosphate buffer. Over the 14 days after surgery there were no significant differences in the rats' body weight or food intake. Deep mesencephalic lesioned rats spilled more food and drank more water (never more than 5 ml more) than controls or pedunculopontine tegmental lesioned rats. Spontaneous locomotion and that elicited by d-amphetamine or apomorphine were not affected by ibotenate lesions of either the pedunculopontine tegmental nucleus or deep mesencephalic nucleus. At higher doses of d-amphetamine and apomorphine, however, excessive biting and licking were observed in the pedunculopontine tegmental nucleus, but not deep mesencephalic nucleus, lesioned rats. Such orofacial stereotypies are never observed in normal rats after systemic injection of d-amphetamine. Post mortem analysis showed that ibotenate lesions of the pedunculopontine tegmental nucleus had destroyed cholinergic and non-cholinergic neurons there but had left the deep mesencephalic nucleus intact; ibotenate lesions of the deep mesencephalic nucleus destroyed neurons in that structure but not the pedunculopontine tegmental nucleus. These data demonstrate that lesions in the pedunculopontine tegmental nucleus and deep mesencephalic nucleus have different effects, measured histologically and behaviourally; that neither spontaneous locomotion nor that stimulated by d-amphetamine or apomorphine is dependent on the integrity of the pedunculopontine tegmental nucleus; and that the pedunculopontine tegmental nucleus plays an important role in mediating orofacial activity stimulated by these drugs. The data are discussed in terms of their implications for understanding outflow from the caudate-putamen and nucleus accumbens.

Animals↗

Failure of naloxone to reverse apomorphine effects in humans.

Twelve male volunteers given apomorphine (20 micrograms/kg/hr) for 40 min by i.v. infusion had significant changes in growth hormone, prolactin, vasopressin, pulse rate, sedation and nausea. Naloxone, (20 mg i.v.) or placebo given in a double-blind manner 10 min before the end of the apomorphine infusion as a concealed bolus did not alter the effects of apomorphine. Vasopressin rise correlated significantly with nausea intensity. We conclude that acute opiate receptor blockade does not reverse most apomorphine effects.

Adolescent↗

Prefrontal cortex and neostriatum self-stimulation in the rat: differential effects produced by apomorphine.

In a dose-response experiment, the effects of intraperitoneal injections of the dopamine receptor agonist, apomorphine (0.075, 0.15, 0.3, 0.6 and 1.2 mg/kg) were studied on self-stimulation elicited from electrodes implanted in the medial and sulcal prefrontal cortex and caudate-putamen in the rat. From the medial and sulcal prefrontal cortex electrodes, apomorphine produced a dose-related decrease of self-stimulation rate which was consistent across animals. From the caudate-putamen electrodes, on the contrary, apomorphine produced a facilitatory effect in the majority of the animals at one or more doses, however, at other doses a decreased self-stimulation rate was observed. The clear and consistent effects of apomorphine on self-stimulation of the prefrontal cortex, together with other experimental evidence in the same line, suggest that dopamine is mediating self-stimulation of this cortical area.

Animals↗

Modulation of apomorphine-induced stereotypy by estrogen: time course and dose response.

Previous data have indicated that estrogen may either suppress or enhance the potency of dopamine and/or dopamine agonists. The effects of estrogen (estradiol benzoate; EB) in ovariectomized rats were indicative of a dose related suppression of apomorphine-induced stereotypy at 24 hours after the last dose of EB. HOwever, at 48 hours after the last dose of EB, the apomorphine-induced stereotypy was enhanced in those animals that received EB at 100 microgram/kg x 3 days. Ninety-six hours after the last injection of EB, all animals that received either the 100 or 50 microgram/kg dose of EB displayed an enhanced behavioral response to apomorphine. Animals pretreated with a low dose of EB (10 microgram/kg x 3 days) displayed a suppressed apomorphine stereotypy score at 24 hours, after the last dose, but were indistinguishable from Oil injected ovariectomized controls in all subsequent behavioral tests. These data indicate that estrogen can suppress dopamine and/or dopamine agonist potency 24 hours after the last dose of estrogen. However, an enhanced behavioral response to dopamine agonists can been seen at 48 hours (or more) after the last dose of estrogen. The time delay and the dose dependence of the enhanced response to dopamine agonists are indicative of a "withdrawal" phenomenon, suggesting the possibility that the role of endogenous estrogen is to suppress dopaminergic function.

Animals↗

Selective effects of apomorphine on dorsal raphe neurons: a cytofluorimetric study.

Using a quantitative cytofluorimetric method to detect changes in the intracellular levels of serotonin (5-HT) in individual neurons in rat brain, we have found that the dopaminergic agonist apomorphine increases 5-HT content of dorsal raphe cell bodies without affecting cells in the median raphe nucleus. Liquid chromatographic studies revealed that apomorphine also elevated the concentrations of both 5-HT and its metabolite 5-hydroxyindoleacetic acid (5-HIAA) in striatum, the projection site for dorsal raphe neurons. Conversely, the dopaminergic antagonist haloperidol, at a dose of 0.8 mg/kg, decreased 5-HT levels in dorsal raphe cells. A lower dose of haloperidol (0.4 mg/kg), which had no significant effect alone, completely blocked the effect of apomorphine in the dorsal raphe. These results support the hypothesis that the effects of apomorphine on serotonergic neurons are secondary to dopamine receptor stimulation.

Animals↗

Increased apomorphine-induced hypothermia precedes development of hypertension in SHRs.

Apomorphine produced a greater hypothermic response in spontaneously hypertensive rats (SHRs) than in normotensive Wistar-Kyoto rats (WKYs). Experiments were conducted in SHRs and WKYs of three age groups to determine whether the increased hypothermic responsiveness to apomorphine occurs prior to the development of hypertension. The mean systolic blood pressures (SBPs) of SHRs and WKYs were comparable at 4-6 weeks of age. The mean SBP of SHRs were significantly greater than that of WKYs at both 8-10 and 12-15 weeks of age. Yet SHRs responded to apomorphine with significantly greater hypothermia than WKYs at all three ages. These findings indicate that the hyperresponsiveness of SHRs to apomorphine-induced hypothermia precedes the development of hypertension. This sequence of events is consistent with the hypothesis that central DA systems play a role in development of hypertension in SHRs.

Aging↗

Role of neostriatum and nucleus accumbens in stepping induced by apomorphine and dexamphetamine.

Systemic administration of apomorphine and dexamphetamine are known to produce circling in rats by changing the functioning of hindlimb stepping and forelimb stepping, respectively. In the present study intracranial injections of the dopamine antagonist sulpiride were used to study the involvement of the neostriatum and nucleus accumbens in these effects. It was found that injections of sulpiride into the neostriatum, but not the nucleus accumbens, dose-dependently (1-20 ng) reduced the number of apomorphine-induced hindlimb doublets without affecting the dexamphetamine-induced forelimb crossing steps. On the other hand, it was found that injections into the nucleus accumbens, but not the neostriatum, reduced the number of dexamphetamine-induced forelimb crossing steps without affecting the apomorphine-induced hindlimb doublets. This effect was not dose-dependent. The data suggest that the neostriatum, but not the nucleus accumbens, is primarily involved in the apomorphine-induced changes in hindlimb stepping, and that the nucleus accumbens, but not the neostriatum, is primarily involved in the dexamphetamine-induced changes in forelimb stepping.

Animals↗

Effect of chronic antidepressant treatment on responses to apomorphine in selectively bred rat strains.

The purpose of this study was to verify the dopamine-sensitizing behavioral effect of chronic antidepressant treatment in two selectively bred rat strains: the hypercholinergic Flinders Sensitive Line (FSL) and control Flinders Resistant Line (FRL). Two antidepressants, desipramine HCl (DMI) and sertraline HCl, were injected IP in separate groups of FSL and FRL rats in a dose of 16.5 mumol/kg twice daily for 16 days. Twenty-four hours after withdrawal, locomotor and hypothermic responses to 0.2 mg/kg of apomorphine, SC, were examined. Attenuation of the effect of apomorphine was observed in the open field: FRLs withdrawn from sertraline were significantly less mobile than control FRLs, and the same trend was found in FSL rats. Chronic DMI resulted in similar changes in the locomotor activity. Sertraline treatment decreased apomorphine-induced hypothermia by almost half in FSLs, whereas slight hyperthermia was induced in FRL rats instead. The present results suggest that in these selectively bred strains, a serotonergic antidepressant such as sertraline may have sensitized dopaminergic autoreceptors and/or desensitized postsynaptic receptors. Apomorphine-induced hypothermia could be mediated by serotonergic neuron function that may have been altered by chronic sertraline but not DMI treatment.

1-Naphthylamine↗

Potentiation of apomorphine-induced climbing behaviour in mice by d-LSD.

1. The climbing behaviour in mice was used for studying possible interaction(s) of d-LSD with dopamine receptors. 2. Doses of d-LSD ranging from 0.25 to 2.5 mg/kg injected intra-peritoneally constantly inhibited the climbing behaviour. 3. In contrast, when similar doses of d-LSD were injected 10 min before apomorphine (5 mg/kg), a constant potentiation of the apomorphine-induced climbing was observed. 4. Subsequent experiments performed with a neuroleptic (haloperidol) or a serotonin precursor (5-OH-tryptophan) compared to those of d-LSD with and without apomorphine would indicate that d-LSD alone displays typical serotoninergic syndrome (including inhibition of the climbing), whereas in the presence of apomorphine, an interaction at presynaptic receptors may possibly modulate dopaminergic activity.

Animals↗

Ganglioside GM1 counteracts the enhancing effects of subacute toluene exposure on apomorphine-induced locomotor activity.

Previous studies indicate that subacute toluene exposure enhances the effects of postsynaptic doses of apomorphine on locomotor activity in the rat. We have now studied the effects of the ganglioside GM1 on toluene-affected apomorphine-induced (1 mg/kg, s.c.) locomotion, motility, and rearing. Treatment with GM1 (10 mg/kg, i.p., 1 h before exposure) was found to counteract or even reverse the enhancing effect of toluene on apomorphine-induced locomotion and rearing, but had similarly to toluene no significant effects on apomorphine-induced motility or on spontaneous locomotor activity. The antagonistic effects of GM1 may be due to its ability to block toluene-induced changes in D2 receptor binding.

Animals↗

Novel liquid chromatographic assay for the low-level determination of apomorphine in plasma.

A novel HPLC assay which is rapid, reproducible and sensitive has been developed for the analysis of apomorphine in plasma. The assay incorporates boldine as an internal standard, and uses solid-phase extraction on C18 mini-columns for sample clean-up and concentration, so enabling quantitation of apomorphine at 500 pg/ml using fluorescence detection (lambda(ex) 270 nm, lambda(em) 450 nm). The HPLC assay comprised a 25 cm-long Techopak C18 column and a mobile phase of (0.25 M sodium dihydrogen phosphate plus 0.25% heptane sulphonic acid, to pH 3.3 with orthophosphoric acid) containing 30% (v/v) methanol and 0.003% (w/v) EDTA, run at a flow-rate of 1.5 ml/min. Calibration plots prepared in plasma were linear over the range 1-30 ng/ml, (limit of quantitation (LOQ) = 490 pg/ml) with R.S.D. of 0.05% and R.E. of 5.0% at the level of 1 ng/ml. Preliminary pharmacokinetic data from two patients given apomorphine by 12 h subcutaneous infusion (patient A dose = 35 mg and patient B dose = 141 mg) showed apomorphine elimination from plasma to fit a two-compartment model, with initial half-lives of 8.2 and 46.6 min, elimination half-lives of 76.4 and 166.5 min and area under the plasma concentration-time curve (AUC) values of 236 and 405 ng h/ml, respectively.

Antioxidants↗

Block by apomorphine of acetylcholine receptor channels expressed in Xenopus oocytes.

Effects of apomorphine and other compounds related to dopamine receptors on nicotinic acetylcholine receptor channels were investigated by expressing functional channels in Xenopus oocytes. When channels were expressed with a combination of alpha 3 and beta 4 subunits, acetylcholine activated an inward current, and apomorphine suppressed the current in a concentration-dependent manner with an IC50 value of about 3 microM. SKF38393 (R(+)-1-phenyl-2,3,4,5-tetrahydro-(1H)-3-benzazepine-7,8-diol; dopamine D1 receptor agonist; 3 and 30 microM), quinpirole (dopamine D2 receptor agonist; 30 microM), SCH23390 (R(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benza zepine; dopamine D1 receptor antagonist; 10 microM) or sulpiride (dopamine D2 receptor antagonist; 10 microM) also inhibited the acetylcholine-activated current whereas dopamine (100 microM) was ineffective. The inhibition by apomorphine of the acetylcholine-activated current was also apparent when alpha 3 subunit was combined with beta 2 subunit instead of beta 4 subunit, or beta 4 subunit was combined with alpha 2 or alpha 4 subunit instead of alpha 3 subunit to express channels. The results suggest that apomorphine blocks acetylcholine receptor channels through a binding site that is similar to, but cannot be included in dopamine receptors. The binding site may not be present in a single specific subunit.

2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-ben↗

Chiral capillary electrophoretic method for quantification of apomorphine.

A new method for chiral determination of apomorphine enantiomers was developed and validated. Seven different neutral and charged cyclodextrins were tested for enantioselectivity on R,S-apomorphine. Sulfobutylether-beta-cyclodextrin was found to offer the best resolution, but with this system, four peaks were detected from a solution of the two enantiomers, which was suggested to be the result of different forms of the complex between the selector and apomorphine. A complexation constant was estimated for a complex of 1:1 ratio for the second and the fourth peak, whereas the other two peaks were fitted to a model ratio of 1:2 (analyte-selector). To avoid this phenomenon, hydroxypropyl-beta-cyclodextrin was then chosen as the chiral selector. An optimisation study was performed on three factors: concentration of the chiral selector, pH of the buffer, and applied voltage. Optimum conditions were: 14 mM of hydroxypropyl-beta-cyclodextrin, pH 3.0, and 16 kV. UV detection was at 200 nm. The method was validated at the chosen conditions, offering a limit of detection of 0.2 microM and a limit of quantification of 0.5 microM. The validated method was applied for the determination of R,S-apomorphine in a transport study with an in vitro cell culture model of the intestinal mucosa (Caco-2).

Apomorphine↗

Apomorphine increases vesicular monoamine transporter-2 function: implications for neurodegeneration.

Apomorphine is a nonselective dopamine D1/D2 receptor agonist used in Europe to treat symptoms resulting from the dopaminergic degeneration associated with Parkinson's disease. In addition, neuroprotective effects of this agent in rodent models have been reported. Recent studies indicate that treatments that alter vesicular monoamine transporter-2 (VMAT-2) function may be protective in models of dopaminergic degeneration. Hence, the purpose of the present study was to examine the effect of apomorphine on VMAT-2 function. Results revealed that apomorphine rapidly and reversibly increased vesicular dopamine uptake, as determined in purified striatal vesicles obtained from treated rats. This increase occurred in both postnatal day 40 and postnatal day 90 rats, and was associated with a redistribution of VMAT-2 protein within nerve terminals. This effect of apomorphine on vesicular dopamine uptake was blocked by pretreating with eticlopride, a dopamine D2 receptor antagonist. The implications of these findings relevant to the treatment of neurodegeneration are discussed.

Animals↗